Literature DB >> 26922571

Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer.

Hee Jin Lee1, Ahrong Kim2, In Hye Song1, In Ah Park1, Jong Han Yu3, Jin Hee Ahn4, Gyungyub Gong1.   

Abstract

High mobility group box 1 (HMGB1) is a prototypic alarmin or damage-associated molecule inducing inflammatory mediator release and immune response. Several studies have revealed the prognostic and predictive importance of tumor-infiltrating lymphocytes (TILs) in breast cancer. The present study analyzed the expression of HMGB1 in each breast cancer subtype and the relationship between the expression level of HMGB1 and pathologic parameters including TILs. Two cohorts were studied: 575 consecutive breast cancer patients who underwent surgery between 1995 and 1998; and 767 triple negative breast cancer (TNBC) patients who underwent surgery between 2004 and 2010. The immunohistochemical expression level of HMGB1 in cytoplasm and nucleus was evaluated using tissue microarrays. High HMGB1 expression in cytoplasm was associated with high histologic grade, pT stage, and abundant TILs in the consecutive breast cancer cohort. Cytoplasmic HMGB1 expression was higher in TNBCs and HER2-positive tumors than in hormone receptor-positive tumors. In the TNBC cohort, high cytoplasmic HMGB1 expression was significantly associated with high histologic grade, abundant TILs, and high numbers of CD8+ cells. However, nuclear HMGB1 expression was not associated with histologic grade or TIL levels. Neither cytoplasmic nor nuclear expression of HMGB1 showed prognostic significance in TNBC. Cytoplasmic HMGB1 expression is associated with TIL levels in breast cancer.
© 2016 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Breast cancer; HMGB1; Tumor infiltrating lymphocytes

Mesh:

Substances:

Year:  2016        PMID: 26922571     DOI: 10.1111/pin.12393

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  10 in total

Review 1.  Targeting HMGB1: An available Therapeutic Strategy for Breast Cancer Therapy.

Authors:  Haonan Dong; Lu Zhang; Suling Liu
Journal:  Int J Biol Sci       Date:  2022-05-09       Impact factor: 10.750

2.  CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer.

Authors:  Heejae Lee; Hee Jin Lee; In Hye Song; Won Seon Bang; Sun-Hee Heo; Gyungyub Gong; In Ah Park
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

3.  Endoplasmic reticulum stress induces secretion of high-mobility group proteins and is associated with tumor-infiltrating lymphocytes in triple-negative breast cancer.

Authors:  In Ah Park; Sun-Hee Heo; In Hye Song; Young-Ae Kim; Hye Seon Park; Won Seon Bang; Suk Young Park; Jeong-Hyon Jo; Hee Jin Lee; Gyungyub Gong
Journal:  Oncotarget       Date:  2016-09-13

4.  miR-505 inhibits proliferation of osteosarcoma via HMGB1.

Authors:  Guangzhang Li; Fajing Liu; Jun Miao; Yongcheng Hu
Journal:  FEBS Open Bio       Date:  2020-05-31       Impact factor: 2.693

5.  New Insights into the Occurrence of Matrix Metalloproteases -2 and -9 in a Cohort of Breast Cancer Patients and Proteomic Correlations.

Authors:  Gianluca Di Cara; Maria Rita Marabeti; Rosa Musso; Ignazio Riili; Patrizia Cancemi; Ida Pucci Minafra
Journal:  Cells       Date:  2018-07-28       Impact factor: 6.600

6.  Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

Authors:  Miseon Lee; In Ah Park; Sun-Hee Heo; Young-Ae Kim; Gyungyub Gong; Hee Jin Lee
Journal:  J Pathol Transl Med       Date:  2019-03-11

7.  Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC.

Authors:  Qun Gao; Shumin Wang; Xinfeng Chen; Shaoyan Cheng; Zhen Zhang; Feng Li; Lan Huang; Yang Yang; Bin Zhou; Dongli Yue; Dan Wang; Ling Cao; Nomathamsanqa Resegofetse Maimela; Bin Zhang; Jane Yu; Liping Wang; Yi Zhang
Journal:  J Immunother Cancer       Date:  2019-02-11       Impact factor: 13.751

8.  miR-142-3p reduces the viability of human cervical cancer cells by negatively regulating the cytoplasmic localization of HMGB1.

Authors:  Hui Dong; Jie Song
Journal:  Exp Ther Med       Date:  2021-01-14       Impact factor: 2.447

9.  HMGB1 Translocation is Associated with Tumor-Associated Myeloid Cells and Involved in the Progression of Fibroblastic Sarcoma.

Authors:  Huoying Chen; Xiaoying Lin; Hongbo Liu; Cheng Huang; Rong Li; Jie Ai; Jiaxue Wei; Shengjun Xiao
Journal:  Pathol Oncol Res       Date:  2021-03-31       Impact factor: 3.201

Review 10.  Johnny on the Spot-Chronic Inflammation Is Driven by HMGB1.

Authors:  Carolina M Gorgulho; Graziela G Romagnoli; Rosh Bharthi; Michael T Lotze
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.